GENEVA, Switzerland and WALTHAM, Massachusetts, September 18 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) and Syntonix Pharmaceuticals Inc. announced today that they have entered into an agreement under which the companies will evaluate Syntonix' FSH:Fc SynFusion(TM) products for further development. Syntonix' SynFusion and Transceptor(TM) technologies may enable the development of a long-acting FSH therapy for the treatment of infertility that can be inhaled and dosed less frequently, instead of injected daily.
